1 **Single-Cell RNA Sequencing Reveals the Altered Landscape of Immune Cells in**

2 **Immune Checkpoint Inhibitor Related Myocarditis**

3 Bowen Lou^{1,2#}, Manyun Guo^{1,2#}, Fangyuan Chen^{1,2#}, Chen Wang^{1,2}, Gulinigaer
4 Tuerhongjiang^{1,2}, Tao Zheng^{1,2}, Bo Zhou^{3*}, and Zuyi Yuan^{1,2*}, Jianqing She^{1,2*}

5

6 1 Cardiovascular Department, First Affiliated Hospital of Xi'an Jiaotong University,
7 Xi'an 710061, Shaanxi, China

8 2 Key Laboratory of Environment and Genes Related to Diseases, Ministry of
9 Education, Xi'an 710061, Shaanxi, China

10 3 Respiratory Department, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
11 710061, Shaanxi, China

12

13 # Contribute equally to the paper.

14 *Correspondence:

15 Jianqing SHE, MD, Email: jianqingshe@xjtu.edu.cn

16 Zuyi YUAN, MD, PhD, Email: zuyiyuan@mail.xjtu.edu.cn

17 Bo ZHOU, MD, PhD, Email: zb_bob@stu.xjtu.edu.cn

18 First Affiliated Hospital of Xi'an Jiaotong University

19 Yanta West 277, Xi'an 710061, Shaanxi, China

20 Fax: +86 029 85323800

21 Phone: +86 029 85323800

22 The authors declare no potential conflicts of interest.

23

24 **Abstract**

25 **Background:** Myocarditis has emerged as a rare but lethal Immune checkpoint
 26 inhibitor (ICI)-associated toxicity. However, the exact mechanism for ICI related
 27 myocarditis remains underexplored; and the specific therapeutic targets is still lacking.
 28 In this study, we used scRNA-seq to characterize the transcriptomic profiles of single
 29 cells from the peripheral blood mononuclear cell (PBMC) of ICI related myocarditis
 30 during fulminant myocarditis and disease recovery.

31 **Methods:** PBMC samples were taken from the patient during fulminant ICI related
 32 myocarditis and after disease remission. Cells were isolated from blood samples by
 33 density gradient centrifugation over Ficoll-Paque. Single-cell RNA sequencing with
 34 10X genomics was performed. Subpopulation determination, functional analysis,
 35 single-cell trajectory and cell-cell interaction analysis were carried out afterwards.

36 **Results:** We presented the altered landscape of immune cells and differential genes in
 37 ICI related myocarditis during the disease activity and remission using scRNA-seq.
 38 Substantial immune cell composition and intercellular communication were found to
 39 be altered. Monocyte, NK cell as well as B cell subpopulations contributed to the
 40 regulation of innate immunity and inflammation in ICI related myocarditis. T cell
 41 subpopulations highly expressed genes associated with PD-1 inhibitor resistance and
 42 hyper-progressor. At last, the intercellular communication in ICI related myocarditis
 43 was significantly dysregulated.

44 **Conclusion:** By identifying altered pathways and highlighting a catalog of marker
 45 genes, this study has revealed the diversity of cellular populations in ICI related

46 myocarditis, marked by their distinct transcriptional profiles and biological functions.

47 Our investigation would shed light on the pathophysiological mechanism and

48 potential therapeutic targets of ICI related myocarditis in continuous exploration.

49

50 **Key Words:** Immune Checkpoint Inhibitor Related Myocarditis, Single-Cell RNA

51 Sequencing, Monocytes, Macrophages, T lymphocytes, B lymphocytes.

52

53 **ABBREVIATIONS AND ACRONYMS**

54 ICI: Immune checkpoint inhibitor

55 PBMC: Peripheral blood mononuclear cell

56 PD-1: Programmed Death Molecule 1

57 PD-L1: Programmed Cell Death 1 Ligand 1

58 TCR: T cell receptor

59 BCR: B cell receptor

60 CDR: Complementary determining region

61 irAEs: immune-related adverse events

62

63 **Introduction**

64 With the revolutionized utilization of Immune checkpoint inhibitor (ICI) therapy
 65 in various malignancies, myocarditis has emerged as a rare but lethal ICI-associated
 66 toxicity, the mortality rate of which approaching 50%. While stimulating an effective
 67 tumor response by blocking the co-inhibitory pathway used by tumor cells to evade
 68 the T cell-mediated immune response, ICI could also elicit profound immune reaction
 69 and cytokine release, causing significant systemic abnormalities, including fulminant
 70 myocarditis^{1, 2}. However, the exact mechanism for ICI related myocarditis remains
 71 underexplored; and the specific therapeutic targets is still lacking. As ICI functions
 72 mainly by interfering T cell-mediated immune response, to investigate an atlas of
 73 peripheral blood cells and characterize their respective functions are essential for
 74 understanding the pathophysiology and developing treatment strategies for ICI related
 75 myocarditis.

76 ScRNA-seq has emerged as a powerful tool for defining cellular components and
 77 functions in various diseases and tissues across a spectrum of tumor and
 78 cardiovascular disease. Recent studies have investigated comprehensive single-cell
 79 landscape of immune cells among Programmed Death Molecule 1 (PD-1) treated
 80 patients as well as animal models. It has been revealed that the hepatitis induced by
 81 combination of ICIs is associated with a robust immune activation signature in all
 82 subtypes of T cells; together with a central role for liver monocyte-derived
 83 macrophages in promoting a pro-inflammatory T cell response³. ScRNA-seq has also
 84 revealed that the homing macrophages expressing unique scavenger molecules are

85 required for the effect of Programmed Cell Death 1 Ligand 1 (PD-L1) blockade⁴.
 86 Moreover, scRNA-seq has further links the durable responses to ICI with T cell
 87 receptor (TCR) repertoire⁵⁻⁷. On the other hand, a comparison of scRNA-seq data from
 88 different autoimmune myocarditis models suggests that some cell clusters such as
 89 macrophage cluster and T-helper cells are associated with the inflammatory response
 90 in the myocarditis⁸. However, data on the single-cell transcriptional profiles and
 91 immunological network of ICI related myocarditis during the disease onset and
 92 remission remain unknown.

93 In this study, we used scRNA-seq to characterize the transcriptomic profiles of
 94 single cells from the peripheral blood mononuclear cell (PBMC) of ICI related
 95 myocarditis during fulminant myocarditis and disease recovery. Our results revealed
 96 the diversity of cellular populations in ICI related myocarditis, marked by their
 97 distinct transcriptional profiles and biological functions. Furthermore, we described
 98 the similarities and differences in the cellular composition during myocarditis onset
 99 and recovery. Our study could serve as an important resource for studying the
 100 potential mechanism and pathophysiology of ICI related myocarditis.

101

102 **Methods**

103 **Study design and eligibility**

104 This study was designed to profile transcriptomic changes in PBMC samples
105 during fulminant ICI related myocarditis and during disease remission. PBMC
106 samples were taken from the patient with myocarditis before any treatment and 28
107 days later when the cardiac lesion markers, echocardiography and inflammatory
108 markers returned to normal (Supplementary Fig 1). The ICI related myocarditis
109 happened 21 days after the utilization of Tislelizumab, a PD-1 inhibitor as a treatment
110 for lung cancer. The diagnose of ICI related myocarditis was based on clinical
111 symptoms, echocardiography and laboratory markers according to the current
112 guidelines^{9, 10}. Written informed consent was obtained from the patient, with ethnic
113 committee approval at the First Affiliated Hospital of Xi'an Jiaotong University.

114 **PBMC collection and library preparation for single-cell RNA sequencing**

115 PBMCs were isolated from blood samples by density gradient centrifugation
116 over Ficoll-Paque, and cryopreserved in 10% dimethyl sulfoxide in fetal bovine serum
117 and stored in liquid nitrogen. Single-cell suspensions were loaded to 10x Chromium
118 to capture 5000 single cells according to the manufacturer's instructions of 10X
119 Genomics Chromium Single-Cell 3'kit (V3). The following cDNA amplification and
120 library construction steps were performed according to the standard protocol.
121 Libraries were sequenced on an Illumina NovaSeq 6000 sequencing system (paired-
122 end multiplexing run, 150bp).

123 **Single-cell RNA sequencing**

124 Quality control and data processing were carried out by LC-Bio Technology
125 (Hangzhou, China). 10X genomics raw data were processed by using the Cell Ranger
126 Single-Cell Software Suite (release 5.0.1), including using cellranger mkfastq for
127 demultiplexing raw base call files into FASTQ files and then using cellranger count
128 for alignment, filtering, barcode counting, and UMI (unique molecular identifier)
129 counting. The reads were aligned to the Homo_sapiens_GRCh38_96 reference
130 genome by using a prebuilt annotation package downloaded from the 10X Genomics
131 website. The outputs from different lanes were finally aggregated by using cellranger
132 aggr with the default parameter settings.

133 We mapped UMIs to genes, followed by removing low-quality cells. Cells were
134 flagged as poor-quality if 1) the number of expressed genes was < 500 and 2) 25% or
135 more UMIs mapped to mitochondrial or ribosomal genes. Cells meeting the latter
136 threshold were usually nonviable or apoptotic. As a result, 8183 and 9546 cells were
137 obtained from fulminant myocarditis and recovered myocardial functions status,
138 respectively. The data were then normalized. Genes with high variation were
139 identified using Seurat function FindVariableFeatures.

140 Principal component analysis(PCA) for dimensional reduction was performed
141 using Seurat function RunPCA. We then used the FindNeighbors and FindClusters
142 (resolution = 0.8)functions in the Seurat package for cell clustering analysis and
143 displayed the 2D map using tSNE.

144 **Subpopulation Analysis**

145 The FindAllMarkers function in Seurat was used to identify unique cluster-

specific marker genes. We first identified PBMC clusters with the dominant expression pattern of cell markers, including monocyte, NK cell, CD4+ T cell, CT8+ T cell, B cell and megakaryocyte, from the online database and published literature. Putative clusters with common canonical markers were integrated into one cluster. Violin plots, heatmaps, and cluster annotations were carried out in Seurat with the corresponding footnotes.

Functional Analysis

To identify the potential biological functions of cell clusters, we performed enrichment analysis with marker genes for cell clusters. Marker genes detected in >10% cells in a cluster with average $\log_2FC \geq 0.26$, $P \leq 0.01$ were used in the analysis. Enrichment analyses were performed using the OmicStudio tools at <https://www.omicstudio.cn/tool>. Cell subpopulations were annotated based on their expressed marker genes, functions, and proportions.

Single-cell trajectory analysis

Single-cell trajectories were constructed by using the Monocle package based on the analysis of the UMI read data. The default settings were used for all other parameters. Pseudotime analysis data were classified into microglial clusters and cell states in different groups.

Cell-cell interaction

We predicted intercellular communication network among different cell populations using CellPhoneDB(<https://pypi.org/project/CellPhoneDB/>). In brief, it uses the UMI count matrix to predict potential interactions of ligand and receptor

168 between each pair of cell populations. The nodes of the network are ligand, receptor,
169 and ECM molecules. The edges of the network are interaction between two molecules.
170 Higher expression levels of ligands and receptors result in larger scores, and imply
171 higher probability and stronger strength of interreactions. We used marker genes with
172 log-fold-change >0.5 in each cell populations to refine the network. The results show
173 the potential specific cell-cell interreaction pathways between two cell
174 populations. To visualize the communication, top 20 ligand-receptor pairs based on
175 predicted interaction scores were selected and plotted.

176 **Statistical Analysis**

177 All statistical analysis was performed in R (Version 3.5.2). $P < 0.01$ was
178 considered as statistical significance. The significance of PCs in the dataset was
179 determined using Seurat function JackStraw via a permutation approach. Differential
180 proportion analysis of cell populations or subpopulations was performed by logit
181 transformation of cell ratios in PBMC, and then t test between each pair. Differential
182 expression of genes between cell clusters were determined with the Wilcoxon rank-
183 sum test using Seurat FindAllMarkers. Overrepresentation tests were performed using
184 clusterProfiler function enrichGO, and P were computed with hypergeometric tests.
185 For differential proportion, differential expression, and enrichment analyses, P were
186 adjusted for multiple hypothesis testing using the Benjamini-Hochberg method.

187 **Availability of Data**

188 The data that support the findings of this study including scRNA-seq data and R
189 scripts for single cell data analysis are available from the corresponding author upon

190 reasonable request. Besides, the RNA-Seq datasets produced in this study are

191 uploading to GEO (Gene Expression Omnibus, NIH) and the accession number will

192 be accessed soon.

193

194 **Results**

195 **ScRNA-seq atlas of cell populations in ICI related myocarditis and recovery** 196 **phase after PD-1 initiation.**

197 To explore the profiling of specific cell populations at the single-cell level,
198 peripheral blood mononuclear cell samples were collected during fulminant ICI
199 related myocarditis onset and after disease remission. A total of 17729 cells were
200 included in the subsequent analysis after quality filtering (Fig 1, A). We identified 17
201 cell clusters including monocytes (4 cell clusters), neutrophils (3 cell clusters), T cells
202 (5 cell clusters), natural killer (NK) cells (6 cell cluster), B cells (1 cell clusters), and
203 platelets (1 cell cluster) using unsupervised graph-based clustering and SingleR (Fig 1,
204 B, Supplementary Fig 2). Each cell cluster exhibited differential percentage (Fig 1,D),
205 indicating that the cellular components of the immune system are fundamentally
206 altered during ICI myocarditis and recovery phase. Different cell types were
207 characterized with marker genes and specific gene expression patterns, such as CD14
208 (Monocyte), NCAM1(NK Cell), CD4 (CD4+ T cell), CD8A (CD8+ T cell) and CD19
209 (B Cell) (Fig 1, C and Fig 2, A). The AREG, NRGN, CXCR4, IL1R2, and RBM38
210 were the top 5 significantly down-regulated genes, and CD8B, S100A12, MND, A,
211 S100A9, TYMP mostly upregulated genes during myocarditis. The violin plots of the
212 relative levels and the location in different cell clusters were shown in Fig 2, B. The
213 NRGN, IL1R2, S100A12, MND, A, S100A9 and TYMP were generally expressed in
214 different clusters of NK cells; CXCR4, RBM38 in NK, T and B cells, AREG in NK
215 cells and CD8B in T cells.

216 **Monocyte subpopulations play inflammatory roles during ICI related** 217 **myocarditis**

218 We detected 4076 monocytes, which were further spilt into 4 clusters (Fig 1, A).
219 The cluster C0 (Mono_1, S100A8⁺), C7 (Mono_2, NEAT1⁺), C11 (Mono_3, NRGN⁺)
220 and C16 (Mono_4, LST1⁺) made up 52.0%, 31.1%, 15.4%, and 2.5% of the entire
221 monocyte population. The clusters were identified to have substantially different
222 proportion during the ICI myocarditis and recovery phase (Fig 3, A), suggesting a
223 distinct transcriptomic profile. The Mono_1 (S100A8⁺) were predominant in ICI
224 related myocarditis, while Mono_2 (NEAT1⁺) and Mono_3 (NRGN⁺) predominant in
225 recovery phase (Fig 3, A). The gene expression pattern was different among monocyte
226 subpopulations, and the marker genes of each subpopulation were shown in Fig 3, B.

227 Trajectory analysis using Monocle2¹¹ arranged most of monocytes into a major
228 trajectory (Figure 3, C). Using Mono_2 (NEAT1⁺) as the root of the trajectory, we
229 found that 2 cellular biology process decision points were dominated by the anti-
230 inflammatory Mono_3 (NRGN⁺), and inflammatory Mono_1 (S100A8⁺) in
231 pseudotime (Figure 3, D). This indicated that upon stimulation of PD-1, monocyte
232 cells undergone pseudotime changes to either inflammatory or anti-inflammatory
233 endpoints. Moreover, based on the differentiation time indicated by the pseudotime
234 trajectory, the gene expression distribution map with 6 predominately differential
235 genes were shown in Figure 3, E. Gradually significantly increased genes during
236 pseudotime trajectory included IFI6, ISG15, S100A11, S100A12, and S100A9; and
237 decreased gene TXNIP.

238 Additionally, the differentially expressed genes between ICI myocarditis and
239 recovery phase were used for GO term enrichment analysis to predict the potential
240 biological process that monocyte took part in during ICI myocarditis. Overall, the
241 monocyte functions were mainly enriched in immune response, cytokine signaling
242 and neutrophil degranulation, etc. during ICI myocarditis (Fig 3, F).

243 **NK cell subpopulations and different clusters contribute to the regulation of** 244 **innate immunity in ICI related myocarditis**

245 NK cell subpopulations separated into 6 subpopulations by first-level t-
246 distributed stochastic neighbor embedding analysis (Fig 4, A). C4 (NK_2, highly
247 expressing CST7, GZMA and GZMB), as well as C5 (NK_3, highly expressing
248 MALAT1, MT-CO1 and MT-ND4L) were predominant in ICIs myocarditis,
249 accounting for 39.04% of the entire NK cells. C1 (NK_1, highly expressing CCL5,
250 and FGFBP2), as well as C6 (NK_4, highly expressing AREG and CD7) composed
251 majority of NK cells during recovery, accounting for 43.88% of the entire NK cells
252 (Figure 4, B).

253 Using trajectory analysis, we noticed that the C12 subpopulation (NK_6,
254 NRGN⁺PPBP⁺) constituted a majority of the root of the trajectory, and C5 (NK_3
255 MALAT1⁺) from myocarditis located at the end of the trajectory (Figure 4, D). The
256 gene expression distribution map with 6 predominately differential genes were shown
257 in Figure 4, C; gradual decrease of CXCR4, RPL11, RPL5, RPS27A and RPS7, and
258 increase of PLEK were identified with pseudotime. With the help of GO enrichment
259 analysis, these NK cells mainly function in immune system processes, protein binding,

260 RNA binding and neutrophil degranulation (Figure 4, D).

261 **T cell cluster may play an essential role in the PD-1 response.**

262 A total of 5072 T cells were identified. Unlike monocytes and NK cells, the
 263 subpopulation of T cells and its compositions remained generally the same during ICI
 264 related myocarditis and recovery phase (Figure 5, A). The mark genes of each
 265 subpopulations were shown in Figure 5, B. Previous report had identified four
 266 different types of gene mutations, which might be related to the efficacy of PD-1
 267 antibody¹²⁻¹⁹. To further investigated the transcriptional changes of T cells in patients
 268 utilizing PD-1 inhibitors and suffering myocarditis, we then analyzed the expression
 269 of genes related to efficacy, resistance, and hyper-progressor in different T cell
 270 subpopulations. Notably, with regard to genes associated with PD-1 inhibitor
 271 resistance, JAK3, JAK1 and B2M were highly expressed in all T cell subpopulations,
 272 and PTEN in T cell_1 CD4⁺IL7R⁺, T cell _2 CD3D⁺CD3G⁺, T cell _3 CD27⁺AQP3⁺,
 273 and T cell _5 NRGN⁺PPBP⁺. The MDM4 related to hyper-progressor was also highly
 274 expressed in T cell_1 CD4⁺IL7R⁺ and T cell _3 CD27⁺AQP3⁺ both during
 275 myocarditis and recovery, and in T cell _5 NRGN⁺PPBP⁺ and T cell _4 MT-CYB⁺
 276 during recovery (Figure 5, C).

277 **Substantial different BCR clone types were identified in ICI related myocarditis**

278 B cells, although only 712 cells identified, were mostly prominently increased
 279 after recovery (Figure 6, A), suggesting that the humoral immunity was of vital
 280 importance for patients to recovery from ICI related myocarditis. As a result, we
 281 carried on to investigate the B cell receptor repertoire during myocarditis and

282 recovery (Figure 6, B). The B cell receptors (BCRs) sequences of each single B cell
283 were assembled from single-cell RNA-seq data using Cell ranger. Substantial
284 different BCR clone types were identified with top 10 shown in Figure 6, C,
285 suggesting that the BCR can react strongly during the ICI related myocarditis, along
286 with B cell stimulation and clonal expansion. In the immune response, B cells could
287 be activated by BCR recognition of antigen and lymphokines secreted by T cells to
288 form effector B cells. There is a region called complementary determining region
289 (CDR) on BCR, in which CDR3 is encoded by V, D and J genes, resulting in the
290 highest diversity of CDR3. As a result, CDR3 V/J region genes could reflect the
291 characteristics of BCR clonal typing. The abundance distribution of V/J gene (IGK,
292 IGL, IGH) during myocarditis and recovery were shown in Figure 6, D. Substantial
293 different V/J gene distributions were observed in ICI related myocarditis as compared
294 to recovery phase.

295 **Dysregulation of intercellular communication may appear in ICI related** 296 **myocarditis**

297 Intercellular communication is based on complex reactions between ligands and
298 their receptors as well as specific cell signal pathways. By utilizing CellphoneDB, we
299 built an intercellular network of potential ligand-receptor interactions among cell
300 populations, aiming to analyze single-cell transcriptome data and explore cellular
301 communication at a more detailed level. The overall intercellular communication
302 between each pair of cell populations were shown in Figure 7, A and B. Six major cell
303 populations (Monocytes, NK cells, CD4⁺ T cells, CD8⁺ T cells, B cells, and

304 Megakaryocytes) have most communication with others in a complicated network.

305 The top 20 protein interaction receptor-ligand pairs were shown in Figure 7, C. Of

306 note, these intercellular communications, including TGF β , HLA, CD74, etc.

307 contributed to intercellular recognition and antigen presentation of the immune system.

308 The disruption of intercellular communication may contribute to the pathogenesis as

309 well as disease remission during ICI related myocarditis.

310

311 Discussion

312 Recently, multiple clinical studies have revealed potential tissue damage
 313 associated with ICI therapy; especially, treatment with ICIs can lead to severe and
 314 disabling inflammatory cardiovascular adverse-events soon after commencement of
 315 therapy²⁰. However, few studies have been reported to obtain mechanistic insight into
 316 the molecular mechanisms of the ICI related myocarditis based on scRNA-seq of the
 317 immune cells. In the present study, we have, to the best of our knowledge, for the
 318 first time presented the altered landscape of immune cells and differential genes in ICI
 319 related myocarditis during the disease activity and remission using scRNA-seq.
 320 Substantial immune cell composition and intercellular communication were found to
 321 be altered based on the following observations: (i) Monocyte, NK cell as well as B
 322 cell subpopulations contribute to the regulation of innate immunity and inflammation
 323 in ICI related myocarditis; (ii) T cell subpopulations highly express genes associated
 324 with PD-1 inhibitor resistance and hyper-progressor; (iii) Intercellular communication
 325 in ICI related myocarditis are significantly dysregulated.

326 ICIs have substantially improved clinical outcomes in multiple cancer types²¹.
 327 ICIs block proteins, such as CTLA-4, PD-1, or PD-L1 (PD-1 attached proteins) that
 328 help control the immune response. Blocking one of these proteins can release the
 329 “brake on the immune system” and enhance the ability of immune cells to attack
 330 tumor cells. However, blocking immune checkpoints to restore antitumor immune
 331 response may also break immune tolerance to self-antigens and induce specific
 332 immune-related adverse events (irAEs)²². The severity of most side effects is mild to

333 moderate, which can be alleviated by general steroid treatment; but some patients may
 334 present with life-threatening side effects²³. The irAEs highlight the fundamental
 335 difference between these drugs and other cancer treatments: conventional treatments
 336 such as chemotherapy directly kill tumor cells, while immunotherapy affect immune
 337 functions. As a result, irAEs can affect any organ and tissue. So far, our understanding
 338 towards irAEs is still limited, and it is still of great clinical challenge to predict the
 339 occurrence and severity of irAEs.

340 In the present study, we have provided a comprehensive spectrum and cell type–
 341 level resolution of peripheral blood cells during ICIs related myocarditis based on
 342 scRNA-seq. High throughput scRNA-seq can realize the isolation and library
 343 construction of tens of thousands of single cells, constructing a global tissue and cell
 344 transcription map. It is noteworthy that although PD-1 is mainly expressed in
 345 activated T cells and B cells, the subpopulations of monocyte and NK are more
 346 remarkably altered and exert their inflammatory function during ICI related
 347 myocarditis as compared to disease remission. These indicate that the tissue
 348 microenvironment affected by PD-1 inhibitor could cause dysregulated autoimmunity;
 349 and the loss of immune tolerance ultimately results in myocarditis.

350 ScRNA-seq has paved the way for the discovery of previously unknown cell
 351 types and subtypes in normal and diseased cardiovascular samples, facilitating the
 352 study of rare cells and the functional roles of immune cells in cardiovascular diseases
 353 such as myocarditis²⁴⁻²⁶. Although we are unable to describe each subtype and its
 354 biological functions in detail herein, it is worthy of attention that some key differential

355 genes express in monocyte, NK cell and B cells instead of T cells. This indicated that
356 the inflammatory monocyte played crucial role in the pathophysiological process of
357 ICI related myocarditis. More importantly, the S100A protein family including
358 S100A8, S100A9, S100A11 and S100A12 are significantly highly expressed in the
359 monocyte subpopulation during ICI related myocarditis. Thus, it is also of clinical
360 value to further investigate function of circulating S100A protein levels for predicting
361 irAEs.

362 The increased B cell cluster together with substantially different B cell receptor
363 repertoire suggest the innate immunity is of crucial importance during the acute
364 disease onset, consistent with previous assumptions^{1,2}. The B cell receptor repertoire
365 diversity is achieved by somatic recombination of immunoglobulin (Ig) genes
366 centrally and by somatic hypermutation and Ig heavy chain class-switching
367 peripherally²⁷. Substantial differences during ICI related myocarditis indicate that
368 there are altered functional gene rearrangements and gene combinations resulting in
369 self-reactive BCRs as well as BCRs with high affinity for exogenous antigens after
370 PD-1 inhibitor initiation. Hence, investigation of BCR repertoires based on larger
371 population is reasonable to provide information on stages of B cell development and
372 shed light on the etiology of B cell pathologies during irAEs.

373 The present scRNA-seq data have also revealed that the subpopulation of
374 peripheral T cells and its compositions remained generally the same during ICI related
375 myocarditis and recovery phase. However, the genes correlated to PD-1 inhibitor
376 resistance and hyper-progressor have been highly expressed during myocarditis. This

377 indicated that the resistance to PD-1 inhibitor treatment might be associated with high
378 incidence of irAEs, and further clinical validation studies are necessary. On the other
379 hand, previous study has also proposed that T-cell infiltration with CD4 and CD8
380 positivity is correlated to lethal myocarditis in combination with myositis in patients
381 receiving nivolumab in combination with ipilimumab²⁸. It is a pity that in the present
382 study, we haven't evaluated the single cell sequencing of the myocardium, and thus
383 we have only researched the conclusion that the innate immunity has been extensively
384 triggered during ICIs related myocarditis. But the single cell data from the
385 myocardium of the patients exhibiting irAEs remain to be elucidated.

386 Intercellular communication analysis indicates that the intercellular recognition
387 and antigen presentation differ during ICI related myocarditis and disease remission.
388 Notably, transforming growth factor β (TGF β) signaling pathways, involved in many
389 cellular processes, including cell growth, cell differentiation and apoptosis take active
390 part in the intercellular communication among NK cells, T cells and monocytes via
391 binding TGF β R1 and TGF β R3. In addition, CD74, as an integral transmembrane
392 molecule in intracellular sorting of MHC class II molecules also play an important
393 role in intercellular communications. Generally, as genes associated with antigen
394 presentation and autoimmune are important ligands, we reasoned that the disruption
395 of intercellular communication in immune cells may contribute to the pathogenesis of
396 irAEs. Previous studies have proved that targeting ligand-receptor interactions (for
397 instance, with ICIs) can provide significant benefits for patients²⁹. However, our
398 knowledge regarding which interactions occur in a tumor and how these interactions

399 affect outcome is still limited. Thus, our results shed light on possible downstream
400 pathways and potential mechanism of irAEs which remain to be in-depth explored.

401 The main limitation of the present study is that it is a descriptive study. We have
402 investigated the single cell profiling only in one patient previously using Tislelizumab
403 due to the rare occurrence of the disease. However, by using the 10x Genomics
404 platform to characterize the transcriptional profiles and functional pathways, we
405 represent the first cell atlas during the onset of ICI related myocarditis and after
406 disease remission, which could be used as a reference for ICI related studies in the
407 future. More investigation should be done in the continuous exploration to reveal the
408 roles of different immune cell populations for promoting and preventing the adverse
409 events subsequent to immune checkpoint inhibitor utilization. By enrolling more
410 samples and spatial information to scRNA-seq data, we believe that further in-depth
411 investigation will improve our understanding of immune response and cell-to-cell
412 interactions in ICI related adverse effects, so as to seek for novel diagnostic markers
413 and targeted treatments.

414 In conclusion, by identifying altered pathways and highlighting a catalog of
415 marker genes, this study has created a cell atlas of PBMC during ICI related
416 myocarditis. We described the characteristics of cell populations, the respective
417 marker genes and functions during the fulminant myocarditis and disease remission.
418 In addition, we identified potential inflammatory cell populations and intercellular
419 communication through vital ligand-receptor pairs, which would fuel advances in
420 further mechanistic investigations. Gene expression changes in immune cell landscape

421 provide a reference for organ toxicities related to ICI. Targeting specific
422 immunological pathways represents a promising approach to treat ICI related
423 myocarditis and other related toxicities. As the therapy of ICI related myocarditis is
424 still limited in clinical practice, our investigation would shed light on the
425 pathophysiological mechanism and potential therapeutic targets in continuous
426 exploration.

427

428 **Ethics approval and consent to participate**

429 Written informed consent was obtained from the patient, with ethnic committee
430 approval at the First Affiliated Hospital of Xi'an Jiaotong University.

431

432 **Acknowledgements**

433 The authors wish to acknowledge the assistance of OmicStudioTM for the scRNA-
434 seq and BCR repertoire analysis.

435

436 **Consent for publication**

437 All authors have reviewed the final version of the manuscript and approve it for
438 publication.

439

440 **Funding**

441 This study was supported by National Natural Science Foundation of China (No.
442 82170464, 82100477), National Key R&D Program of China (2019YFA0802300,

443 2018YFC1311505), Key Research and Development Program of Shaanxi (No.
 444 2021KWZ-25, S2020-YF-GHMS-0014, 2020GXLH-Y-015), Central University
 445 Basic Science Foundation of China (119132971000056); and the Clinical Research
 446 Award of the First Affiliated Hospital of Xi'an Jiaotong University, China (No.
 447 XJTU1AF-CRF-2018-025, XJTU1AF-CRF-2017-006).

448

449 **Authors' contributions**

450 JS, BZ and ZY participated in the design of the study. BL, MG FC and TZ
 451 collected the patients' data and extracted the PBMC. BL, CW, GT and MG performed
 452 the statistical analysis. JS, BZ and BL drafted the manuscript. All authors approved
 453 the final manuscript.

454

455 **Conflicts of Interest**

456 Not applicable.

457

458

459 **Figure legends**

460 **Figure 1. scRNA-seq atlas of cell populations in ICI related myocarditis and**
461 **recovery phase after PD-1 initiation.**

462 A. Schematic diagram of PBMC collection during fulminant ICI related myocarditis
463 onset and after disease remission; B. tSNE visualization of individual cell clusters
464 from PBMC of ICI myocarditis and recovery phase using unsupervised graph-based
465 clustering and SingleR; C. tSNE plots highlighting the marker gene of each cluster
466 and cell-type; D. Differential percentage of each cluster between ICI related
467 myocarditis and recovery phase.

468
469 **Figure 2. Top 10 marker genes and top 5 upregulated and downregulated genes**
470 **in ICI related myocarditis and recovery phase after PD-1 initiation.**

471 A. Heatmap of Top 10 differentially expressed genes among all detected subclusters;
472 B. The violin plots of top 5 upregulated and downregulated genes in ICI related
473 myocarditis(right, red column) and recovery phase(left, blue column) after PD-1
474 initiation in different cell clusters.

475
476 **Figure 3. Monocyte subpopulations and its function in ICI related myocarditis**
477 **and recovery phase.**

478 A. tSNE plots of different monocyte subpopulations during the ICI myocarditis and
479 recovery phase, each color corresponds to different monocyte subpopulation/subtype
480 as the right panel showed; B. Dot plot showing the markers of each monocyte

481 subpopulation. Dot size corresponds to proportion of cells within the group expressing
 482 each gene, and dot color corresponds to expression level; C. Trajectory analysis of
 483 monocytes using Monocle2. Dot color corresponds to pseudotime; D. Pseudotime
 484 trajectory analysis of four subtypes of macrophages by using Mono_2 (NEAT1⁺) as
 485 the root, each point indicates one single cell; E. Expressions of differential marker
 486 genes across four subtypes of monocytes; F. GO term enrichment analysis of main
 487 monocyte functions during ICI myocarditis.

488

489 **Figure 4. NK cell subpopulations and its function in ICI related myocarditis and**
 490 **recovery phase.**

491 A. tSNE plots of different NK cell subpopulations during the ICI myocarditis and
 492 recovery phase, each color corresponds to different NK cell subpopulation/subtype as
 493 the right panel showed; B. Dot plot showing the markers of each NK cell
 494 subpopulation. Dot size corresponds to proportion of cells within the group expressing
 495 each gene, and dot color corresponds to expression level; C. Trajectory analysis of NK
 496 cell using Monocle2, dot color corresponds to pseudotime; D. Pseudotime trajectory
 497 analysis of six subtypes of NK cell by using Mono_2 (NEAT1⁺) as the root, each
 498 point indicates one single cell; E. Expressions of differential marker genes across six
 499 subtypes of NK cell; F. GO term enrichment analysis of main NK cell functions
 500 during ICI myocarditis.

501

502 **Figure 5. T cell subpopulations and the expression of genes related to PD-1**

503 **response.**

504 A. tSNE plots of different T cell subpopulations during the ICI myocarditis and
505 recovery phase, each color corresponds to different T cell subpopulation/subtype as
506 the right panel showed; B. Dot plot showing the markers of each T cell subpopulation.
507 Dot size corresponds to proportion of cells within the group expressing each gene, and
508 dot color corresponds to expression level; C. The expression of genes related to
509 efficacy, resistance, and hyper-progressor in different T cell subpopulations; D. GO
510 term enrichment analysis of main NK cell functions during ICI myocarditis.

511

512 **Figure 6. BCR clone types identified in ICI related myocarditis.**

513 A. tSNE plots of B cells during the ICI myocarditis and recovery phase; B. Diversity
514 plot of B cell receptor repertoire during myocarditis and recovery; C. Top 10
515 substantial different BCR clone types were identified through BCRs sequences using
516 Cell ranger; D. The abundance distribution of V/J gene (IGK, IGL, IGH) during
517 myocarditis and recovery.

518

519

520 **Figure 7. Dysregulation of intercellular communication in ICI related**
521 **myocarditis.**

522 A. Overall intercellular communication between each pair of cell populations; B.
523 Most ligand-receptor pairs communication among six major cell populations with
524 others (Monocytes, NK cells, CD4⁺ T cells, CD8⁺ T cells, B cells, and

525 Megakaryocytes) in a complicated network; C. The top20 protein interaction receptor-
526 ligand pairs of different cell types between the ICI myocarditis and recovery phase.

527 **Supplementary Figure 1. Clinical markers alteration during fulminant**
528 **myocarditis and recovery.**

529 A. Levels of IL-6, Troponin T and CK-MB during the treatment; B. The immune
530 subsets evaluated by the immunofluorescence assay.

531

532 **Supplementary Figure 2. Clinical markers alteration during fulminant**
533 **myocarditis and recovery.**

534 tSNE plot of clinical markers alteration during fulminant myocarditis and recovery
535 using unsupervised graph-based clustering and SingleR.

536

537

538

539

540

541

542 Reference

- 543 1. Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L and Kitis RN. Immune checkpoint inhibitor-
544 associated myocarditis: manifestations and mechanisms. *J Clin Invest.* 2021;131.
- 545 2. Stein-Merlob AF, Rothberg MV, Ribas A and Yang EH. Cardiotoxicities of novel cancer
546 immunotherapies. *Heart.* 2021;107:1694-1703.
- 547 3. Llewellyn HP, Arat S, Gao J, Wen J, Xia S, Kalabat D, Oziolor E, Virgen-Slane R, Affolter T and
548 Ji C. T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse
549 model. *J Hepatol.* 2021;75:1083-1095.
- 550 4. Rosenzweig N, Dvir-Szternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-
551 Raynal P, Cahalon L, Kertser A, Baruch K, Amit I, Weiner A and Schwartz M. PD-1/PD-L1 checkpoint
552 blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy
553 mouse model. *Nat Commun.* 2019;10:465.
- 554 5. Kidman J, Principe N, Watson M, Lassmann T, Holt RA, Nowak AK, Lesterhuis WJ, Lake RA
555 and Chee J. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint
556 Therapy Responses. *Front Immunol.* 2020;11:587014.
- 557 6. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH,
558 Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A,
559 Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V,
560 Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA,
561 Boland GM, Sullivan RJ, Getz G and Hacohen N. Defining T Cell States Associated with Response to
562 Checkpoint Immunotherapy in Melanoma. *Cell.* 2018;175:998-1013 e20.
- 563 7. Fairfax BP, Taylor CA, Watson RA, Nassiri I, Danielli S, Fang H, Mahe EA, Cooper R,
564 Woodcock V, Traill Z, Al-Mossawi MH, Knight JC, Klenerman P, Payne M and Middleton MR.
565 Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint
566 blockade in patients with metastatic melanoma. *Nat Med.* 2020;26:193-199.
- 567 8. Hua X, Hu G, Hu Q, Chang Y, Hu Y, Gao L, Chen X, Yang PC, Zhang Y, Li M and Song J.
568 Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis.
569 *Circulation.* 2020;142:384-400.
- 570 9. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad
571 L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I,
572 Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M and Ernstoff MS. Society
573 for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-
574 related adverse events. *J Immunother Cancer.* 2021;9.
- 575 10. Thompson JA. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related
576 Toxicity. *J Natl Compr Canc Netw.* 2018;16:594-596.
- 577 11. Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA and Trapnell C. Reversed graph embedding
578 resolves complex single-cell trajectories. *Nat Methods.* 2017;14:979-982.
- 579 12. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bosse D, Wankowicz SM,
580 Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME,
581 Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG, Jr., Choueiri TK and Van Allen
582 EM. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
583 *Science.* 2018;359:801-806.
- 584 13. Zhang K, Hong X, Song Z, Xu Y, Li C, Wang G, Zhang Y, Zhao X, Zhao Z, Zhao J, Huang M,

585 Huang D, Qi C, Gao C, Cai S, Gu F, Hu Y, Xu C, Wang W, Lou Z, Zhang Y and Liu L. Identification of
586 Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC. *Clin*
587 *Cancer Res.* 2020;26:3649-3661.

588 14. Jiang T, Jia Q, Fang W, Ren S, Chen X, Su C, Zhang L and Zhou C. Pan-cancer analysis identifies
589 TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment. *Clin Transl*
590 *Med.* 2020;10:e109.

591 15. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB,
592 Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM,
593 Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N,
594 Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ,
595 Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-
596 Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M,
597 Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA,
598 Wistuba, II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Janne PA, Stephens PJ, Rudin CM,
599 Geese WJ, Albacker LA and Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in
600 KRAS-Mutant Lung Adenocarcinoma. *Cancer Discov.* 2018;8:822-835.

601 16. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X,
602 Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu
603 TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC,
604 Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Jr., Bosenberg MW, Woodman SE,
605 Overwijk WW, Lizee G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA
606 and Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. *Cancer Discov.*
607 2016;6:202-16.

608 17. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS,
609 Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B,
610 Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Jr., Tumei PC, Graeber
611 TG, Lo RS, Comin-Anduix B and Ribas A. Primary Resistance to PD-1 Blockade Mediated by JAK1/2
612 Mutations. *Cancer Discov.* 2017;7:188-201.

613 18. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
614 Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B,
615 Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B,
616 Comin-Anduix B, Graeber TG, Tumei PC, Schumacher TN, Lo RS and Ribas A. Mutations Associated
617 with Acquired Resistance to PD-1 Blockade in Melanoma. *N Engl J Med.* 2016;375:819-29.

618 19. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A and Kurzrock R. Hyperprogressors
619 after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. *Clin*
620 *Cancer Res.* 2017;23:4242-4250.

621 20. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A,
622 Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB and Moslehi JJ. Cardiovascular toxicities
623 associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance
624 study. *Lancet Oncol.* 2018;19:1579-1589.

625 21. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha
626 L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino
627 MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ and
628 Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review

629 and Meta-analysis. *JAMA Oncol.* 2018;4:1721-1728.

630 22. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Leonard-Louis S,
631 Benveniste O, Moslehi JJ and Allenbach Y. Immune Checkpoint Inhibitor-Associated Myositis:
632 Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. *Circulation.*
633 2018;138:743-745.

634 23. Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M and Reynolds KL. Immune-Related Adverse
635 Events (irAEs): Diagnosis, Management, and Clinical Pearls. *Curr Oncol Rep.* 2020;22:39.

636 24. Jackson-Weaver O, Ungvijanpunya N, Yuan Y, Qian J, Gou Y, Wu J, Shen H, Chen Y, Li M,
637 Richard S, Chai Y, Sucov HM and Xu J. PRMT1-p53 Pathway Controls Epicardial EMT and Invasion.
638 *Cell Rep.* 2020;31:107739.

639 25. Monsanto MM, Wang BJ, Ehrenberg ZR, Echeagaray O, White KS, Alvarez R, Jr., Fisher K,
640 Sengphanith S, Muliono A, Gude NA and Sussman MA. Enhancing myocardial repair with
641 CardioClusters. *Nat Commun.* 2020;11:3955.

642 26. Heinrichs M, Ashour D, Siegel J, Buchner L, Wedekind G, Heinze KG, Arampatzi P, Saliba AE,
643 Cochain C, Hofmann U, Frantz S and Campos Ramos G. The healing myocardium mobilizes a distinct
644 B-cell subset through a CXCL13-CXCR5-dependent mechanism. *Cardiovasc Res.* 2021;117:2664-
645 2676.

646 27. Wu YC, Kipling D and Dunn-Walters D. Assessment of B Cell Repertoire in Humans. *Methods*
647 *Mol Biol.* 2015;1343:199-218.

648 28. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I,
649 Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola
650 N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchok BA, Lichtman AH, Roden DM, Seidman
651 CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Jr., Anders RA, Sosman JA and
652 Moslehi JJ. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N Engl J Med.*
653 2016;375:1749-1755.

654 29. Kumar MP, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond DC, Lauffenburger DA and Raue A.
655 Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor
656 Characteristics. *Cell Rep.* 2018;25:1458-1468 e4.

Figure 2: Top 10 marker genes and top 5 upregulated and downregulated genes in ICI related myocarditis and recovery phase after PD-1 initiation.

Figure 3. Monocyte subpopulations and its function in ICH-related myocarditis and recovery phase.

Figure 4 NK cell subpopulations and its function in IC related myocarditis and recovery phase

Figure 5: T cell subpopulations and the expression of genes related to PD-1 response

Figure 7 Dysregulation of intercellular communication in IC-related myocarditis

Supplementary Figure 1. Clinical markers alteration during fulminant myocarditis and recovery.

Supplementary Figure 2. Clinical markers alteration during fulminant myocarditis and recovery.